SAN DIEGO, California — August 6, 2025 — Leads & Copy — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company, announced its second-quarter financial results for the period ending June 30, 2025, and highlighted recent clinical progress. A first patient was treated in a company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis.
The company continues execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases. Initial safety, translational data, and lead indication selection for AlloNK in autoimmune diseases are expected by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026. The company reports a cash runway into Q2 2027, with cash, cash equivalents, and investments of $142.4 million as of June 30, 2025.
According to Fred Aslan, M.D., CEO of Artiva, the company is making meaningful progress across its ongoing clinical trials exploring AlloNK® in autoimmune disease and looks forward to sharing initial translational data by the end of 2025.
Recent business highlights include activity at over a dozen clinical sites enrolling across two company-sponsored trials in autoimmune diseases: the Phase 2a basket clinical trial and the Phase 1/1b clinical trial in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN).
Upcoming milestones include initial safety and translational data for AlloNK + mAb across multiple autoimmune diseases from ongoing clinical trials and disclosure of lead indication for further development by Year-End 2025, and initial clinical response data in the lead autoimmune indication from ongoing clinical trials with longer follow-up to inform registrational strategy during the first half of 2026.
Financial results indicate that as of June 30, 2025, Artiva had cash, cash equivalents, and investments of $142.4 million, which is expected to fund operations into Q2 2027. Research and development expenses were $17.9 million for the three months ended June 30, 2025, compared to $12.3 million for the three months ended June 30, 2024. The net loss totaled $21.3 million for the three months ended June 30, 2025, as compared to a net loss of $17.8 million for the three months ended June 30, 2024.
Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com; Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
